-
The ECG in the image was obtained during a first visit with an elderly new patient who gave a history of having "lots of heart disease."
-
-
Aggressive LDL lowering with statins, so-called "very intensive statin therapy," leads to reversal of coronary atherosclerosis, according to a new study.
-
Lenalidomide, an analog of thalidomide has been approved for use in selected patients with transfusion dependant myelodysplastic syndrome.
-
Quinolones have become some of the most popularly prescribed antibiotics in the United States.
-
The use of a steroid ointment following a 20-minute soak may relieve chronic skin conditions.
-
Illnesses produced by vascular diseases are far and away the most common cause of death in the developed world and, amazingly enough, will become the leading cause of death even in the developing world by 2020.1 Identifying individuals at increased risk of coronary artery heart disease (CHD) is critical in preventing CHD and, in 2002, the Adult Treatment Panel III (ATP III)2 reaffirmed its previous position by concluding that low-density lipoprotein cholesterol (LDL-C) would remain the cornerstone of lipid management.
-
This case series and prospective observational study describe propylene glycol toxicity in patients receiving IV benzodiazepines. The authors estimate the incidence of this important but unrecognized complication to be 19%.
-
The FDA has approved the first of a new class of agents, the vaptans. Conivaptan, the first arginine vasopressin receptor antagonist, is approved for the management of serious sodium/water imbalance. It will be marketed by Astellas Pharma US, Inc as Vaprisol®.
-
Efficacy and Safety of Benazepril for Advanced Chronic Renal Insufficiency; Prognostic Value of Thyroid Hormone Levels in Acute MI: Just an Epiphenomenon?; Nonsteroidal Anti-inflammatory Drugs and the Risk of Actinic Keratoses and Squamous Cell Cancers of the Skin
